Kiniksa Pharmaceuticals International (KNSA) Non-Current Deffered Revenue (2018 - 2026)

Kiniksa Pharmaceuticals International (KNSA) has 6 years of Non-Current Deffered Revenue data on file, last reported at $31.8 million in Q2 2026.

• Quarterly Non-Current Deffered Revenue changed 0.0% year-over-year to $31.8 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $31.8 million (changed 0.0% YoY) and the FY2025 annual result came in at $31.8 million, changed 0.0% from the prior year.
• Non-Current Deffered Revenue held at $31.8 million in Q2 2026, from $31.8 million in the prior quarter.
• In the past five years, Non-Current Deffered Revenue ranged from a high of $31.8 million in Q4 2024 to a low of $11.8 million in Q2 2024.
• A 5-year average of $19.8 million and a median of $12.2 million in 2023 frame the typical range for Non-Current Deffered Revenue.
• Annual changes were most pronounced in 2023 — Non-Current Deffered Revenue retreated 16.38% — and 2025, when it soared 169.61%.
• Tracing KNSA's Non-Current Deffered Revenue over 5 years: stood at $12.0 million in 2022, then climbed by 2.17% to $12.3 million in 2023, then jumped by 159.45% to $31.8 million in 2024, then changed by 0.0% to $31.8 million in 2025, then changed by 0.0% to $31.8 million in 2026.
• The last three Non-Current Deffered Revenue figures came in at $31.8 million (Q2 2026), $31.8 million (Q1 2026), and $31.8 million (Q4 2025), per Business Quant data.